{"id":"W3087466624","doi":"10.1016/s1470-2045(20)30541-6","title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":498,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre hospitalier universitaire de Québec; McMaster University; Université Laval; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"Foundation Medicine; EMD Serono; Pharmacyclics; Genentech; AstraZeneca; EUSA Pharma; Astellas Pharma; Eisai; INOVIO Pharmaceuticals; AstraZeneca España; Pfizer; Incyte; Ipsen; Clovis Oncology; Les Laboratories Pierre Fabre; Endocyte; Sanofi; Exelixis; GlaxoSmithKline; Celldex Therapeutics; Amgen; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Tremelimumab; Chemotherapy; Metastatic Urothelial Carcinoma; Oncology; Open label; Internal medicine; Urology; Carcinoma; Randomized controlled trial; Urothelial carcinoma; Cancer; Immunotherapy; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005186896,0.0005252264,0.002032255,0.00009416519,0.0001653972,0.00007219124,0.000503529,0.0001449167,0.0003237716],"category_scores_gemma":[0.000424835,0.000307977,0.00007014356,0.00055918,0.000273793,0.0002039387,0.0001563044,0.0004565531,0.00002582885],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005817219,"about_ca_system_score_gemma":0.001532187,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007294038,"about_ca_topic_score_gemma":0.001467395,"domain_scores_codex":[0.9963966,0.0007890033,0.0007138422,0.0007811916,0.0004827287,0.0008366596],"domain_scores_gemma":[0.9979019,0.0006872502,0.000324076,0.0005491864,0.0001763628,0.000361244],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9603977,0.003200248,0.001155982,0.0001357913,0.0007469211,0.0004199976,0.002624563,0.00003311913,0.0002087759,0.00001272337,0.0004553691,0.03060878],"study_design_scores_gemma":[0.9419318,0.04964035,0.001755336,0.0001134089,0.0009722415,0.00003358674,0.0002965972,0.001289783,0.0003219243,0.00001701613,0.003293934,0.0003339624],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9803576,0.0007159325,0.00006101171,0.004371427,0.0002791409,0.01245093,0.0001453621,0.00008938685,0.001529133],"genre_scores_gemma":[0.992108,0.000628259,0.001492399,0.003836087,0.0003951862,0.001029817,0.0001379339,0.0001037399,0.0002686076],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04644011,"threshold_uncertainty_score":0.9999372,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09417910979039026,"score_gpt":0.3763797989152469,"score_spread":0.2822006891248566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}